This proof-of-principle study provides a preclinical tool to screen drug responses to standard-of-care and newly identified, repurposed compounds.
Selected stromal markers of osteoblastic PCa indicate a conserved mechanism of tumor cells to induce a stromal pre-metastatic signature with high potential prognostic or diagnostic value.
This proof-of-principle study provides a preclinical tool to screen drug responses to standard-of-care and newly identified, repurposed compounds.